The European Medicines Agency (EMA) has published its 2025 Annual Report, highlighting a particularly strong year for veterinary medicines, with a record number of new authorisations and continued growth in vaccine development.
Record number of approvals
In 2025, EMA recommended 30 veterinary medicines for marketing authorisation, matching the record set in 2024 and marking the second consecutive year with the highest number of recommendations. Notably, 13 products contained a new active substance not previously authorised in the EU, reflecting ongoing innovation in animal health.
Vaccines at the forefront
Vaccines accounted for more than half of all approvals. EMA recommended 16 veterinary vaccines, up from 14 in 2024, including several developed using biotechnology. Seven vaccines were authorised under exceptional circumstances to help address animal health emergencies, underlining the growing importance of preventive approaches to disease control.
Supporting innovation and limited markets
Interest in products for limited veterinary markets also remained strong. Applications for limited-market classification increased to 17 in 2025, reflecting continued efforts to improve the availability of treatments for less common species, serious diseases and unmet veterinary needs.
Continued focus on medicine safety
Alongside authorisation activities, EMA maintained its pharmacovigilance work through the EudraVigilance system. The number of adverse drug reaction reports remained stable in 2025, supporting the ongoing monitoring of veterinary medicine safety across the EU.
A digital report is available here, and includes a chapter on veterinary medicines.
(photo ©Pixabay)